Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3607MR)

This product GTTS-WQ3607MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3607MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12109MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ1696MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ10380MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ2751MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ7936MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ11359MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ8119MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ6222MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW